Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.33 +1.5%	$1.42	$0.65 ▼ $17.00	$14.14M	1.19	326,514 shs	162,707 shs
DTIL Precision BioSciences	$4.71 -1.3%	$4.67	$3.61 ▼ $11.09	$55.52M	1.52	167,211 shs	106,424 shs
HOWL Werewolf Therapeutics	$1.33 +0.8%	$1.23	$0.60 ▼ $4.18	$59.68M	0.63	207,762 shs	239,697 shs
UNCY Unicycive Therapeutics	$4.70 +1.5%	$5.22	$2.75 ▼ $11.00	$59.41M	1.88	382,440 shs	563,583 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	0.00%	+8.13%	-16.61%	+56.77%	-90.98%
DTIL Precision BioSciences	0.00%	+7.53%	+1.51%	0.00%	-47.43%
HOWL Werewolf Therapeutics	0.00%	+13.68%	-5.00%	+19.82%	-33.17%
UNCY Unicycive Therapeutics	0.00%	+14.91%	+1.08%	-21.13%	+48.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	2.8768 of 5 stars	3.3	4.0	0.0	2.2	0.8	1.3
DTIL Precision BioSciences	4.1234 of 5 stars	3.5	1.0	4.6	3.4	1.7	0.6
HOWL Werewolf Therapeutics	3.5866 of 5 stars	3.5	5.0	0.0	2.1	3.3	0.6
UNCY Unicycive Therapeutics	2.6328 of 5 stars	3.7	2.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,884.96% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	897.88% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	526.57% Upside
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,176.60% Upside

Current Analyst Ratings Breakdown

Latest CTXR, HOWL, DTIL, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$6.35 per share	N/A
DTIL Precision BioSciences	$1.26M	44.03	N/A	N/A	$2.89 per share	1.63
HOWL Werewolf Therapeutics	$1.14M	52.22	N/A	N/A	$1.65 per share	0.81
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.06	N/A	N/A	-60.03%	-33.83%	N/A
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
HOWL Werewolf Therapeutics	-$70.51M	-$1.64	N/A	N/A	N/A	N/A	-99.71%	-58.64%	N/A
UNCY Unicycive Therapeutics	-$36.73M	-$4.12	N/A	N/A	N/A	N/A	-246.71%	-116.96%	N/A

Latest CTXR, HOWL, DTIL, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HOWL Werewolf Therapeutics	-$0.50	-$0.40	+$0.10	-$0.40	$1.50 million	N/A
8/14/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/12/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	-$0.80	-$0.04	-$0.80	$1.92 million	$1.92 million
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.47	0.06
DTIL Precision BioSciences	0.66	5.18	5.18
HOWL Werewolf Therapeutics	0.46	8.09	8.09
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
DTIL Precision BioSciences	37.99%
HOWL Werewolf Therapeutics	64.84%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
DTIL Precision BioSciences	4.50%
HOWL Werewolf Therapeutics	23.60%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
HOWL Werewolf Therapeutics	40	44.87 million	34.28 million	Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

CTXR, HOWL, DTIL, and UNCY Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 17 at 12:33 PM | globenewswire.com

Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS

August 16 at 5:50 PM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 16 at 10:00 AM | prnewswire.com

Unicycive Therapeutics Raises $16.3 Million in Stock Sale

August 15 at 12:22 AM | msn.com

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

August 14 at 12:07 AM | msn.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 4:14 PM | gurufocus.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 3:55 PM | globenewswire.com

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics expects cash to fund operations into 2H of 2026

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 13, 2025 | globenewswire.com

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

August 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 11, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 9, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Holdings Lifted by Vivo Capital LLC

August 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 6, 2025 | prnewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 1,211.2% in July

August 3, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 31, 2025 | prnewswire.com

Unicycive Therapeutics Inc Ordinary Shares UNCY - Morningstar

July 30, 2025 | morningstar.comM

Unicycive Therapeutics (NASDAQ:UNCY) Trading Down 6.2% - Here's What Happened

July 30, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR, HOWL, DTIL, and UNCY Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.33 +0.02 (+1.53%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.34 +0.01 (+1.13%)

As of 08/15/2025 07:46 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Precision BioSciences NASDAQ:DTIL

$4.71 -0.06 (-1.26%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.69 -0.02 (-0.42%)

As of 08/15/2025 07:51 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Werewolf Therapeutics NASDAQ:HOWL

$1.33 +0.01 (+0.76%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.32 -0.01 (-0.38%)

As of 08/15/2025 05:47 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Unicycive Therapeutics NASDAQ:UNCY

$4.70 +0.07 (+1.51%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.72 +0.02 (+0.43%)

As of 08/15/2025 07:57 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time